Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center

Published 2011 View Full Article

Authors

Keywords

Journal

CRITICAL CARE MEDICINE

Volume 40, Issue 1, Pages 104-111

Publisher

Ovid Technologies (Wolters Kluwer Health)

Online

2011-10-05

DOI

10.1097/ccm.0b013e31822e9d66

Ask authors/readers for more resources

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

CRITICAL CARE MEDICINE

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Create your own webinar

Ask a Question. Answer a Question.